Abbott Laboratories entered into an agreement with Spain-based global biotech company mAbxience Holdings S.L. to commercialize several biosimilars focusing on oncology, women’s health, and respiratory diseases in emerging markets. The first molecules are expected to launch in 2025, while others are subject to the completion of clinical development and registration. Abbott will register and commercialize the biosimilars in key emerging countries in Latin America, Southeast Asia, the Midd...